Praliciguat is a potent soluble guanylate cyclase stimulator belonging to the class of non-peptide vasodilators, currently under investigation for its therapeutic potential in treating heart failure with… Read more
Praliciguat is a potent soluble guanylate cyclase stimulator belonging to the class of non-peptide vasodilators, currently under investigation for its therapeutic potential in treating heart failure with reduced ejection fraction. By activating soluble guanylate cyclase, this compound increases cyclic GMP levels to promote nitric oxide production, smooth muscle relaxation, and improved cardiac output. This category provides essential reference standards and research compounds, including stable isotope labelled derivatives like Praliciguat-d6, which serve as critical internal standards for quantitative bioanalysis. Pharmaceutical laboratories and researchers utilize these high-quality compounds for comprehensive impurity profiling, rigorous method validation, and consistent quality control during the development and testing of analytical procedures. These materials ensure accurate identification and quantification of the parent drug and its related substances, supporting precise tracking of pharmacokinetics and metabolic pathways throughout the drug development lifecycle.